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Abstract
Introduction: Concurrent prescribing of opioids and benzodiazepines is discouraged by 
evidence-based clinical guidelines because of the known risks of taking these medications in 
combination.
Methods: This study analyzed concurrent opioid and benzodiazepine prescribing in 9 states 
using the 2015 Prescription Behavior Surveillance System, a multistate database of de-identified 
prescription drug monitoring program data. Concurrent prescribing rates were examined among 
individuals with both an opioid and a benzodiazepine prescription. Among patients with 
concurrent prescribing, total days of opioid supply, daily dosage of opioids, and total days of 
concurrent prescriptions were examined. Analyses were stratified by whether concurrent 
prescribing was from a single prescriber or multiple prescribers. Opioid prescribing and 
concurrent opioid and benzodiazepine prescribing rates were examined by age and sex. Analyses 
were conducted in 2018.
Results: Among 19,977,642 patients that were prescribed an opioid, 21.6% (4,324,092) were 
also prescribed a benzodiazepine, of which 54.9% (2,375,219) had concurrent prescriptions. More 
than half of patients with concurrent opioids and benzodiazepines received prescriptions from 2 or 
more distinct prescribers. Mean total opioid days, daily opioid dosage, and days of concurrent 
prescribing were higher among patients when multiple prescribers were involved compared with 
concurrent prescriptions from the same prescriber. Concurrent prescribing was more common 
among adults aged ≥50 years and female patients.
Conclusions: Public health interventions are needed to reduce concurrent prescribing of opioids 
and benzodiazepines. Evidence-based guidelines can help reduce concurrent prescribing when one 
prescriber is involved, and utilization of prescription drug monitoring programs and improved care 
coordination could help address concurrent prescribing when multiple prescribers are involved.
INTRODUCTION
Although opioid analgesics are the most common drugs involved in prescription drug 
overdose deaths, benzodiazepines often play a contributing role, and are involved in 
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approximately one third of all opioid overdose deaths in the U.S.1 When taken together, 
opioids and benzodiazepines can result in synergistic respiratory depression and 
substantially increase the risk of drug overdose.1–5 In an effort to decrease the use of opioids 
and benzodiazepines together, the U.S. Food and Drug Administration added a boxed 
warning to the drug labeling of prescription opioids and benzodiazepines in 2016.6
Despite reductions in opioid prescribing in the U.S.,7 concurrent prescribing of opioids and 
benzodiazepines remains common.4,8–10 From 2002 to 2014, the proportion of opioid 
recipients in the U.S. who were dispensed a benzodiazepine concurrently rose by 41%, with 
approximately half of patients receiving both prescriptions from the same prescriber on the 
same day.8 Further, a retrospective analysis of privately insured claims data from 2001 to 
2013 found that concurrent opioid and benzodiazepine prescribing increased from 9% in 
2001 to 17% in 2013.4 Nearly 3% of all emergency room encounters receiving an opioid 
prescription also received a benzodiazepine prescription.10 In addition, a study using 
national laboratory test results indicated concurrent use of opioids and benzodiazepines in 
more than 25% of patients in 2015.11
The trend in concurrent opioid and benzodiazepine prescribing also parallels a rising trend in 
emergency department visits and drug overdose deaths in which both opioids and 
benzodiazepines are implicated.1 From 2004 to 2011, the rate of emergency department 
visits involving nonmedical use of both opioid analgesics and benzodiazepines rose from 
11.0 to 34.2 visits per 100,000, and during this same period, drug overdose deaths involving 
both opioids and benzodiazepines increased from 0.6 to 1.7 per 100,000.1
Although previous studies provide information on the trends and frequency of concurrent 
opioid and benzodiazepine prescribing,8 limited information exists on how frequently these 
overlapping episodes result from a single provider versus multiple providers. In addition, 
limited information exists on the patient characteristics, frequency, dosage, and duration of 
concurrent prescribing.12 Such information could be helpful in understanding the patterns of 
concurrent prescribing of opioids and benzodiazepines and help inform prevention efforts. 
Implications for prevention efforts could be different based on the number of prescribers 
involved in overlapping opioid/benzodiazepine episodes. For example, evidence-based 
guidelines, such as the “CDC Guideline for Prescribing Opioids for Chronic Pain” (Centers 
for Disease Control [CDC] Prescribing Guideline),13 which recommends a high degree of 
caution when prescribing an opioid in combination with a benzodiazepine, could be more 
helpful in reducing concurrent prescribing when one prescriber is involved, as opposed to 
multiple providers unaware of each other’s prescriptions. Meanwhile, prescription drug 
monitoring programs (PDMPs), electronic databases used to monitor the prescribing and 
dispensing of controlled substance, and care coordination may be more effective when 
concurrent prescribing is the result of multiple prescribers. Understanding the characteristics 
of patients with an overlapping episode can help identify effective interventions and better 
target efforts to reduce the concurrent prescribing of opioids and benzodiazepines. The 
objectives of this study are the following: (1) to examine the number of distinct prescribers 
involved in concurrent opioid and benzodiazepine prescribing episodes; (2) to investigate the 
days of opioid use, daily dosage of opioids, and duration of concurrent prescribing; and (3) 
to analyze the demographic characteristics of patients with concurrent prescriptions.
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METHODS
Data from PDMPs were obtained through the Prescription Behavior Surveillance System 
(PBSS) at Brandeis University. PBSS is a longitudinal database of de-identified PDMP data 
from multiple states that have collected statewide PDMP data. PBSS was created to serve as 
an early warning public health surveillance tool and a database for evaluation of state and 
local policies and interventions aimed at improving the prescribing of controlled substances. 
CDC determined this study to be exempt from human subject regulations and IRB approval.
The PBSS contains information regarding all in-state filled controlled substance 
prescriptions that are received by a state PDMP. Information includes de-identified patient 
ID, de-identified prescriber ID, de-identified pharmacy ID, dispensing date, days of supply, 
quantity dispensed, drug name, National Drug Code, patient birthday, patient sex, and 
geographic information of the patient and the pharmacy. Availability of this information 
varies by state. Brandeis University calculated the total dosage and daily dosage of all opioid 
prescriptions as morphine milligram equivalents (MMEs). MME conversion factors have 
been published elsewhere.14
Study Population
The current study includes 2015 PDMP data from 9 of the 11 states participating in PBSS: 
California, Delaware, Florida, Idaho, Kentucky, Maine, Ohio, Virginia, and West Virginia. 
Two states were excluded because prescription information needed (e.g., prescriber ID) for 
the analysis was not available. Data from 2015 were used, as they were the most current data 
available for analysis. Out-of-state residents who filled opioid or benzodiazepine 
prescriptions in 1 of the 9 states were excluded from the analysis.
Measures
Individuals with at least one opioid prescription were identified. Overall opioid prescribing 
rates were calculated using 2015 population estimates from the U.S. Census Bureau for each 
of the 9 states. Among individuals with an opioid prescription, the percentage with at least 
one benzodiazepine prescription in 2015 was examined. Opioid and benzodiazepine 
prescriptions were identified using their National Drug Code codes. Buprenorphine 
products, typically used for substance use disorder treatment, were excluded from the 
analysis.7 Methadone used for the treatment of opioid use disorder at methadone clinics is 
not available in PDMP data.
The rate of concurrent prescribing was examined among individuals who had both an opioid 
and a benzodiazepine prescription. Concurrent prescribing was defined as having any opioid 
and benzodiazepine prescriptions, which overlapped for at least 7 consecutive days.8,15–17 
Concurrent prescriptions did not have to be dispensed on the same day. De-identified 
prescriber ID was used to identify the source of prescriptions. If an individual had 
concurrent prescriptions from the same prescriber during the year, the source of concurrent 
prescriptions was defined as one prescriber; otherwise, the source of concurrent 
prescriptions was defined as multiple prescribers (i.e., different prescribers).
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Three characteristics of concurrent opioid and benzodiazepine prescriptions were examined 
among individuals who had concurrent opioid and benzodiazepine prescriptions: total days 
of opioid supply, daily dosage of opioids, and total days of concurrent prescribing. Total 
days of opioid supply were calculated as the total number of calendar days during the year 
that an individual had an opioid supply. Individuals with overlapping opioid prescriptions 
were assumed to take them concurrently. Thus, given the definition, total days of opioid 
supply could only be equal to or greater than the total days of concurrent prescribing, and it 
could not exceed 365 days. Daily dosage of opioids was defined as the total dosage of opioid 
prescriptions of an individual divided by total days of opioid supply. High daily dosage of 
opioids was defined as daily dosage ≥90 MMEs per day.13 Total days of concurrent 
prescribing was defined as total days of overlapping opioid and benzodiazepine 
prescriptions. When an individual had more than one occurrence of concurrent prescribing 
during the year, total days of concurrent prescribing was obtained by adding up each 
occurrence. If multiple opioid prescriptions overlapped with a single benzodiazepine or 
multiple benzodiazepines prescriptions overlapped with a single opioid, an overlapping day 
was only counted once to avoid double counting.
Statistical Analysis
Means were calculated for total days of opioid supply, daily dosage of opioids, and total 
days of concurrent prescriptions stratified by prescriber sources of concurrent opioid and 
benzodiazepine prescriptions (one prescriber versus multiple prescribers). To test for 
differences across the measures, t-tests were used. Rates of opioid prescribing and 
concurrent opioid and benzodiazepine prescribing were examined by age and sex. All 
analyses were conducted in SAS, version 9.4, and Stata, version 14.2. Analyses were 
conducted in 2018.
RESULTS
In 2015, across the 9 states, 20.0 million patients (22.3% of their total population) were 
dispensed an opioid (Table 1). The rate of opioid prescriptions varied at the state level from 
20.8% in Delaware to 24.9% in Virginia and West Virginia. In 2015, among patients 
prescribed an opioid, 21.6% were also prescribed at least one benzodiazepine. The rate of 
benzodiazepine prescriptions among opioid patients ranged from 19.5% in Virginia to 26.5% 
in West Virginia. Among patients prescribed both an opioid and a benzodiazepine, 54.9% 
had concurrent prescriptions. The rate of concurrent prescribing varied at the state level from 
46.1% in Idaho to 65.1% in West Virginia.
In each of the 9 examined states, more than half of patients with concurrent opioids and 
benzodiazepines received prescriptions from 2 or more distinct prescribers (Figure 1). The 
involvement of 2 or more prescribers in a concurrent episode was most common in Delaware 
(66.9%), Maine (64.8%), and Ohio (64.1%), and least common in West Virginia (52.4%) 
and California (53.2%).
The characteristics of concurrent opioid and benzodiazepine prescriptions varied by state 
and the number of prescribers involved. Across the 9 states, mean total days of opioid supply 
were higher when the concurrent prescriptions were from 2 or more prescribers (153.1 days) 
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compared with when 1 prescriber was involved (118.8 days, p<0.001). Kentucky had the 
highest number of mean total days of opioid supply across both categories, an average of 
218.8 days when the concurrent prescriptions were from 2 or more prescribers and 201.9 
days when 1 prescriber was involved.
The mean daily dosage of opioids was higher among patients when the concurrent 
prescriptions were from 2 or more prescribers (71.4 MMEs/day) compared with concurrent 
prescriptions from the same prescriber (63.9 MMEs/day, p<0.001) (Table 2). The mean daily 
dosage of opioids was highest in Maine when the concurrent prescriptions were from 
multiple prescribers (83.1 MMEs/day) and highest in California when 1 prescriber was 
involved (70.5 MMEs/day).
The mean total days of concurrent prescribing was higher among patients when the 
concurrent prescriptions were from multiple prescribers (101.2 days) compared with 
concurrent prescriptions involving one prescriber (77.6 days, p<0.001). Kentucky had the 
highest mean days of concurrent prescribing across both categories, an average of 157.0 
days when the concurrent prescriptions were from multiple prescribers and 148.7 days when 
the concurrent prescriptions were from the same prescriber.
The rates of opioid prescribing and concurrent prescribing of opioids and benzodiazepines 
varied by age and sex (Table 3). The greatest percentages of patients with opioid 
prescriptions were aged 50–64 years (28.4%) and ≥65 years (25.9%). Similarly, the greatest 
share of patients with concurrent opioid and benzodiazepine prescriptions were aged 50–64 
years (37.6%) and ≥65 years (34.6%).
DISCUSSION
Concurrent prescribing of opioids and benzodiazepines puts individuals at greater risk for 
overdose.1–5 This study shows that among individuals prescribed an opioid in 2015 in 9 
PBSS states, nearly 1 in 4 were also prescribed a benzodiazepine during the year. Among 
those prescribed both medications during the year, 55% were prescribed opioids and 
benzodiazepines concurrently.
Almost half of patients with concurrent prescriptions for opioids and benzodiazepines 
obtained both medications from the same prescriber. When one prescriber is involved, 
evidence-based guidelines, such as the CDC Prescribing Guideline, which discourages the 
concurrent prescribing of opioids and benzodiazepines,18 may be effective in reducing this 
prescribing behavior. In fact, research has shown that the release of the CDC Prescribing 
Guideline was associated with a reduction in the percentage of patients receiving 
overlapping opioid and benzodiazepine prescriptions.18 Given the greater risks of 
benzodiazepine withdrawal relative to opioid withdrawal, when patients receiving both 
benzodiazepines and opioids require tapering to reduce overdose risk, it might be safer and 
more practical to taper opioids first.13 Therefore, clinicians should communicate with mental 
health professionals managing the patient to discuss the patient’s needs, prioritize patient 
goals, weigh risks of concurrent benzodiazepine and opioid exposure, and coordinate care.13 
Despite the lower risk of opioid withdrawal, it is important to avoid abrupt tapering or 
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sudden discontinuation of opioids, as these practices can result in severe opioid withdrawal 
symptoms and some patients seeking other sources of opioids.19
More than half of concurrent opioid and benzodiazepine prescribing instances resulted from 
prescriptions involving 2 or more distinct prescribers. Furthermore, when patients obtained 
concurrent prescriptions from 2 or more prescribers, they tended to have more total days of 
opioid supply, higher daily dosages of opioids, and more total days of concurrent 
prescriptions, compared with patients who obtained concurrent prescriptions from one 
prescriber. These findings have several important implications. First, among patients 
prescribed opioids, higher opioid doses are associated with an increased risk of opioid 
overdose death.20–22 Second, patients receiving opioids for longer durations are at higher 
risk for long-term use and developing opioid use disorder.23,24 Third, higher daily dosage 
and longer duration of concurrent prescriptions might indicate that prescribers were not 
aware of all other opioids or benzodiazepines that their patients were prescribed, thus 
reducing the likelihood of engaging in risk mitigation strategies. The concurrent prescribing 
of opioids and benzodiazepines by multiple prescribers highlights the importance of PDMPs 
in avoiding concurrent prescribing, and the importance of reviewing PDMPs before 
prescribing controlled substances to mitigate risk and improve coordination of care. PDMPs 
allow prescribers to view a patient’s prescribing history to determine if a patient has a 
current prescription from a different prescriber. Some states, including California in October 
2018, have mandated checking the PDMP before prescribing any controlled substance. 
Evidence has shown that PDMPs, particularly those mandating provider review before 
prescribing opioids, are associated with lower rates of opioid prescribing and lower opioid 
overdose rates.25–27
Although there was little variation across the states in opioid prescribing rates and patients 
receiving both opioids and benzodiazepines, more variation was observed in the rate of 
concurrent prescribing and the characteristics of concurrent prescriptions. For instance, the 
rate of concurrent prescribing varied from 65% in West Virginia to 46% in Idaho. The 
number of prescribers involved in concurrent prescribing also varied substantially across 
states. For example, in Delaware, 67% of patients concurrently prescribed opioid and 
benzodiazepines obtained them from 2 or more prescribers, compared with 52% in West 
Virginia. Among patients with concurrent prescriptions, the mean total days of opioid supply 
and mean days of concurrent prescribing in Kentucky were twice that of California. 
However, although California had the lowest mean days of concurrent prescribing, it had the 
second highest mean daily dosage of opioids among patients with concurrent prescribing. 
These variations indicate that, in addition to national efforts to address the high-risk 
concurrent prescribing of opioids and benzodiazepines, tailored and targeted intervention 
efforts, such as educational outreach to opioid prescribers (academic detailing), could be 
impactful given the heterogeneous patterns of concurrent prescribing at the state level.
Female patients were more likely to be prescribed opioids, as well as concurrent opioid and 
benzodiazepine prescriptions, than male patients. These findings are consistent with 
evidence showing that female patients seek medical care more often than male patients and 
have a higher prevalence of chronic pain, mental health conditions, and anxiety—conditions 
for which these medications are commonly prescribed.8,28–31 The largest percentage of 
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individuals with concurrent opioid and benzodiazepine prescriptions were older adults, aged 
50–64 years (37.6%) and ≥65 years (34.6%). This finding is consistent with previous 
research showing that benzodiazepine prescribing increases with age.32 Although drug 
overdose rates tend to be lowest among older adults, the concurrent use of opioids and 
benzodiazepines among older adults is associated with other risk factors, including falls and 
injuries.33–36
Though this study provides important insights into the concurrent prescribing of opioids and 
benzodiazepines, it also highlights important areas for future research. Given the association 
between PDMP characteristics and prescribing behaviors,25,26 future research is needed to 
examine how PDMP characteristics, such as mandatory use, are associated with the 
concurrent prescribing of opioid and benzodiazepines. In addition, future research could 
examine patient characteristics associated with the concurrent prescribing of opioid and 
benzodiazepines. Together, this information could help identify effective interventions and 
target efforts to reduce the number of individuals concurrently prescribed an opioid and a 
benzodiazepine.
Limitations
This study is subject to several limitations. First, the clinical context and indications for the 
concurrent prescribing of opioids and benzodiazepines cannot be determined. Second, the 
data used in this study represent dispensed prescriptions, and information is not available on 
actual medication use. Third, data are not available on medication use without a prescription. 
Previous research has indicated that in more than half of patients with positive laboratory 
test results for concurrent opioid and benzodiazepine use, one drug was prescribed, whereas 
the other was nonprescribed.11 Fourth, prescriptions dispensed out-side of the state are not 
captured. Fifth, the cross-sectional nature of the study limits the ability to examine factors 
associated with cross-state variation in concurrent prescribing rates. Lastly, the data used in 
the present study examine prescribing behaviors occurring before the release of the CDC 
Prescribing Guideline in March 2016. Although the percentage of patients with overlapping 
opioid and benzodiazepine prescriptions has been declining in recent years, particularly after 
the release of the CDC Prescribing Guideline,18 it is important to continue monitoring 
changes in concurrent prescribing.
CONCLUSIONS
Concurrent prescribing of opioids and benzodiazepines is common, despite the known risks 
of taking these medications in combination. The findings in this study highlight the need for 
public health actions to reduce concurrent prescribing. Evidence-based guidelines, such as 
the CDC Prescribing Guideline, could be helpful in reducing this prescribing behavior when 
one prescriber is involved. Meanwhile, the utilization of PDMPs and care coordination could 
help address concurrent prescribing when multiple prescribers are involved.
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Figure 1. 
Distribution of concurrent opioid and benzodiazepine prescribing by the number of 
prescribers involved. CA, California; DE, Delaware; FL, Florida; ID, Idaho; KY, Kentucky; 
ME, Maine; OH, Ohio; VA, Virginia; WV, West Virginia.
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Table 3.
Demographic Characteristics Among Patients With Opioids and Patients With Concurrent Opioid and 
Benzodiazepine Prescriptions
Variable Patients with an opioid, % Patients with concurrent prescriptions, %
Age, years
 <18 3.1 0.3
 18–34 20.5 7.4
 35–49 22.1 20.1
 50–64 28.4 37.6
 ≥65 25.9 34.6
Sex
 Male 41.2 34.1
 Female 58.8 65.9
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